title: Different potency of bacterial antigens TLR2 and TLR4 ligands in stimulating mature mast cells to cysteinyl leukotriene synthesis.
abstract: The aim of study was to compare the potency of different bacterial antigens to induce rat mature mast cell to cysteinyl leukotriene (cysLT) generation. We examined Toll-like receptor (TLR)2 agonists, i.e. lipoteichoic acid (LTA) Staphylococcus faecalis, Streptococcus pyogenes, Bacillus subtilis and Staphylococcus aureus, lipoarabinomannan (LAM) Mycobacterium smegmatis, peptydoglican (PGN) Staphylococcus aureus, as well as TLR4 agonists, i.e. lipopolysaccharide (LPS) Klebsiella pneumoniae, Pseudomonas aeruginosa, Salmonella enteritidis, Pophyromonas gingivalis and Escherichia coli. We also estimated the effect of tumor necrosis factor (TNF)-, interleukin (IL)-6-, CCL5-, and IL-10-priming on mast cell cysLT synthesis following bacterial antigen activation. We found that all bacterial antigens activated mast cells to cysLT generation; however, the extent of cysLT release in response to stimulation varied. Out of the examined antigens LPS P. gingivalis exhibited the highest potency, as it induced cysLT generation acting at a very low concentration (10(-4)  ng/mL). Other LPSs affected mast cells at higher (up to 10(5) -fold) concentrations. LTAs were the most effective at concentrations of 5 × 10(2)  ng/mL, while LAM and PGN stimulated mast cells to maximal cysLT generation at concentrations as high as 10(5)  ng/mL. Anti-TLR2 and anti-TLR4 antibodies, as well as nuclear factor κB (NF-κB) inhibitor significantly diminished cysLT generation in response to bacterial antigen stimulation. Priming with TNF, IL-6 and CCL5 did not affect bacterial antigen-induced cysLT generation, while IL-10-pretreatment caused significant decrease in cysLT synthesis by mast cells. These observations might have a great pathophysiological importance; inasmuch cysLTs strongly influence the development and intensity of inflammation during bacterial infection.
authors.affiliation: Department of Experimental Immunology, Medical University of Łódź, Łódź, Poland.
authors.forename: Edyta
authors.initials: E
authors.lastname: Bąbolewska
authors.forename: Piotr
authors.initials: P
authors.lastname: Witczak
authors.forename: Anna
authors.initials: A
authors.lastname: Pietrzak
authors.forename: Ewa
authors.initials: E
authors.lastname: Brzezińska-Błaszczyk
mesh_terms: D000818:Animals; D000942:Antigens, Bacterial / Q000276:immunology*; D003545:Cysteine / Q000096:biosynthesis*; D016207:Cytokines / Q000276:immunology; D005260:Female; D015289:Leukotrienes / Q000096:biosynthesis*; D008070:Lipopolysaccharides / Q000276:immunology; D008407:Mast Cells / Q000276:immunology*; D010457:Peptidoglycan / Q000276:immunology; D051381:Rats; D017208:Rats, Wistar; D013682:Teichoic Acids / Q000276:immunology; D051195:Toll-Like Receptor 2 / Q000819:agonists*; D051197:Toll-Like Receptor 4 / Q000819:agonists*
chemical_list: D000942:Antigens, Bacterial; D016207:Cytokines; D015289:Leukotrienes; D008070:Lipopolysaccharides; D010457:Peptidoglycan; D013682:Teichoic Acids; C495343:Tlr2 protein, rat; C495347:Tlr4 protein, rat; D051195:Toll-Like Receptor 2; D051197:Toll-Like Receptor 4; C112381:cysteinyl-leukotriene; C009900:lipoteichoic acid; D003545:Cysteine